Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III/IV Randomized Open-Label Two Cohort Trial to Evaluate irAEs with Different Standard of Care Dosing Strategies of Pembrolizumab or Nivolumab
Study Type: Treatment
Phase: III
NCTID: NCT07174453
Principal Investigator:
Anup Kasi
A Phase II Randomized Study of Ruxolitinib vs Prednisone as First-Line Therapy for Chronic Graft vs Host Disease cGVHD Needing Systemic Therapy
Study Type: Treatment
Phase: II
NCTID: NCT06660355
Principal Investigator:
Muhammad Umair Mushtaq
An Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction with Melphalan/HDS Followed by Trifluridine?tipiracil plus Bevacizumab Versus Trifluridine?tipiracil plus Bevacizumab Alone in Patients with Refractory Metastatic Colorectal Cancer with Liver Dominant Disease
Study Type: Treatment
Phase: II
NCTID: NCT06607458
Principal Investigator:
Gregory Crane
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
Study Type: Prevention
Phase: III
NCTID: NCT06513962
Principal Investigator:
Keith August
PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer ES-SCLC
Study Type: Treatment
Phase: II
NCTID: NCT06769126
Principal Investigator:
Anusha Chidharla
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
Study Type: Treatment
Phase: III
NCTID: NCT06124157
Principal Investigator:
Keith August
A Multicenter, Open-Label, Phase I Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis PMF, Post-Polycythemia Vera Myelofibrosis PPV-MF, or Post-Essential Thrombocythemia Myelofibrosis PET-MF Who Have Been Failed by a Type I JAK2 Inhibitor JAK2i
Study Type: Treatment
Phase: I
NCTID: NCT06343805
Principal Investigator:
Abdulraheem Yacoub
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
Study Type: Treatment
Phase: II
NCTID: NCT03739814
Principal Investigator:
Kenneth Byrd
A Phase III, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study Type: Treatment
Phase: III
NCTID: NCT06973187
Principal Investigator:
Marc Hoffmann
A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery NEOPOLIS
Study Type: Treatment
Phase: II
NCTID: NCT07195734
Principal Investigator:
Omar Karadaghy